AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 526348: 3,4,7-Tribromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 3,4,7-tribromodibenzofuran. Molecular Formula: C12H5Br3O. Molecular Weight: 404.88. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528938: 4-(1,1,3,3-Tetramethylbutyl)phenyl trimethylsilyl ether

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]silane. Molecular Formula: C17H30OSi. Molecular Weight: 278.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Evaluation Brief: Evaluating Systems and Organizational Change in Child Welfare Settings

This brief explores challenges and strategies for evaluating systems and organizational change in child welfare settings. Drawing on current evaluation literature and the experiences of federally funded child welfare grantees, it highlights several key steps in the evaluation process, including articulation of a theory of change, formulating clear research questions, and identifying appropriate data indicators and benchmarks of progress.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 529739: Methyl 2,3-dichloro-4-oxopentenoate

Chemical compound data from PubChem database. IUPAC Name: methyl 2,3-dichloro-4-oxopentanoate. Molecular Formula: C6H8Cl2O3. Molecular Weight: 199.03. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525496: 5-Methyl-4-thia-1-heptyne

Chemical compound data from PubChem database. IUPAC Name: 2-prop-2-ynylsulfanylbutane. Molecular Formula: C7H12S. Molecular Weight: 128.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Creating Healthy Places Intervention Locations

<b>Note: This dataset is no longer updated.</b> This dataset contains the locations of Creating Healthy Places interventions. Creating Healthy Places to Live Work and Play (CHP2LWP) is a joint five year grant (October 2010 – October 2015) of New York State Department of Health’s Division of Chronic Disease Prevention and Division of Nutrition. The Purpose of the initiative is to implement community level interventions to promote healthy lifestyles to prevent obesity and type 2 diabetes. Twenty-two communities across New York State are funded to carry out this initiative. From a list of 18 policy, systems and environmental interventions, community contractors selected a minimum four to implement. The 18 interventions are grouped into five, broad activity categories. The activities include two that are related to increasing opportunities for physical activity, two that address improving nutrition, and one that addresses both physical activity and nutrition.
Patent AT-E400484-T1: [Translated] PASSENGER SUSPENSION SYSTEM FOR CABLE CARS

The passenger conveying unit (3) enables a person to be conveyed on an aerial cableway in a hang glider-like posture with a free view downwards. The passenger conveying unit is mounted to pivot and rotate relative to the cable (1) of the aerial cableway. The unit has a support element (4) to accommodate the passenger and a safety device (5) for the secure connection of the passenger to the conveying unit. The conveying unit is fixed on a suspension (2) which otherwise serves for the connecting of a aerial cable car or is fixed direct to a cable car.
Compound 527145: N-tert-butyl-2-methylpropan-1-amine

Chemical compound data from PubChem database. IUPAC Name: N-tert-butyl-2-methylpropan-1-amine. Molecular Formula: C8H19N. Molecular Weight: 129.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
January Office Hours: Participation in the Pilot and Use of NCWDMS for AFCARS 2020 Reporting

The Children's Bureau Data Analytics and Reporting Team held their first AFCARS Open Office Hours in 2023. These sessions are for state and tribal program administrators, child welfare data leaders, and information system programmers. It provides an opportunity to ask questions specific to your agency's implementation of AFCARS 2020. The January session was presented by the NCWDMS team on how to participate in the pilot and use the National Child Welfare Data Management System (NCWDMS) for AFCARS 2020 reporting.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E400712-T1: [Translated] COVERING DEVICE FOR FLOOR COVERINGS

A profiled cover for floor covering is made from an extruded profile and has a covering flange and at least one clamping web which protrudes downward from the covering flange, extends in the longitudinal direction of the profiled cover, and is used for fastening the profiled cover in a fixture. The cover also comprises a compensating strip fastened to the profiled cover by means of a form-fitting tongue and groove joint. The tongue and groove joint is formed by at least one longitudinal groove in an underside of the covering flange for retaining a tongue in the compensating strip, all sections of the covering flange lying flat over the floor covering they cover.
Patent AT-E40174-T1: [Translated] WINDOW WITH ATTACHED RAIL GRILLE.

1. A window having a superimposed glazing-bar lattice wherein the glazing bars (1, 5) are connected at the cross-connection points by pins (6) which project from a glazing bar (5) in alignment at both sides and by pushing the glazing bars, formed by hollow bars and extending transversely (1) thereto, onto the pins (6), characterised in that each pin (6) is a separate member which projects with two fingers (8) into two parallel bores (3) passing through a glazing bar (1) and that screws (13) holding the two pins (6) together extend through the fingers (8).
A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells

Background
          Bruton's tyrosine kinase (Btk) is essential for B cell development and function. Mutations of Btk elicit X-linked agammaglobulinemia in humans and X-linked immunodeficiency in the mouse. Btk has been proposed to participate in B cell antigen receptor-induced signaling events leading to activation of phospholipase C-γ2 (PLCγ2) and calcium mobilization. However it is unclear whether Btk activation is alone sufficient for these signaling events, and whether Btk can activate additional pathways that do not involve PLCγ2. To address such issues we have generated Btk:ER, a conditionally active form of the kinase, and expressed it in the PLCγ2-deficient DT40 B cell line.
        
        
          Results
          Activation of Btk:ER was sufficient to induce multiple B cell signaling pathways in PLCγ2-sufficient DT40 cells. These included tyrosine phosphorylation of PLCγ2, mobilization of intracellular calcium, activation of extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) mitogen-activated protein kinase (MAPK) pathways, and apoptosis. In DT40 B cells deficient for PLCγ2, Btk:ER activation failed to induce the signaling events described above with the consequence that the cells failed to undergo apoptosis.
        
        
          Conclusions
          These data suggest that Btk:ER regulates downstream signaling pathways primarily via PLCγ2 in B cells. While it is not known whether activated Btk:ER precisely mimics activated Btk, this conditional system will likely facilitate the dissection of the role of Btk and its family members in a variety of biological processes in many different cell types.
Glycopyrrolate oral solution

Glycopyrrolate Oral Solution is a prescription medication containing glycopyrrolate (1 mg per 5 mL), an anticholinergic drug that helps reduce excessive saliva production and certain stomach secretions. Manufactured by Taro Pharmaceuticals U.S.A. Inc., it's approved under ANDA212467 for oral use. This information was generated using AI and is provided for informational and research purposes only.
National Survey of Substance Abuse Treatment Services (N-SSATS-2012)

<p>The National Survey of Substance Abuse Treatment Services (N-SSATS) is designed to collect information from all facilities in the United States, both public and private, that provide substance abuse treatment. N-SSATS provides the mechanism for quantifying the dynamic character and composition of the United States substance abuse treatment delivery system. The objectives of N-SSATS are to collect multipurpose data that can be used to assist the Substance Abuse and Mental Health Services Administration (SAMHSA) and state and local governments in assessing the nature and extent of services provided and in forecasting treatment resource requirements, to update SAMHSA's Inventory of Behavioral Health Services (I-BHS), to analyze general treatment services trends, and to generate the online Substance Abuse Treatment Facility Locator <a href="http://findtreatment.samhsa.gov">http://findtreatment.samhsa.gov</a>, as well as the National Directory of Drug and Alcohol Abuse Treatment Programs.Data are collected on topics including facility operation, services offered (assessment, testing, transitional, ancillary, and pharmacotherapies), detoxification, primary focus (substance abuse, mental health, both, general health, and other), Opioid Treatment Programs and medications dispensed/prescribed, counseling and therapeutic approaches, standard operating procedures, special programs/groups offered, languages in which treatment is provided, type of treatment provided (hospital inpatient, residential, outpatient), number of clients (by service, total, and under age 18), number of beds, types of payment accepted, sliding fee scale, and facility accreditation and licensure/certification.This study has 1 Data Set.</p>
Patent AT-E400539-T1: [Translated] METHOD FOR CONTINUOUSLY PRODUCING A PERFLUORALKYLIODIDE TELOMER

The present invention relates to a process for continuously producing a perfluoroalkyl iodide represented by the general formula Rf(CF2CF2)nI, wherein Rf is a C1-6 perfluoroalkyl and n is an integer from 1 to 4, the method comprising continuously supplying a perfluoroalkyl iodide as a telogen represented by the general formula RfI, wherein Rf is as defined above, and tetrafluoroethylene as a taxogen to a tubular reactor packed with a metal catalyst comprising a powdery spherical metal or a sintered metal; and conducting telomerization at a temperature of 60 to 160 DEG C under a pressure of 0.1 to 5 MPa (gauge pressure). <??>According to the present invention, medium-chain perfluoroalkyl iodides can be continuously and efficiently produced with little generation of impurities, such as hydrogen-containing organic compounds and the like.
Compound 529440: 5-Phenylhexa-1,4-dien-2-ylbenzene

Chemical compound data from PubChem database. IUPAC Name: 5-phenylhexa-1,4-dien-2-ylbenzene. Molecular Formula: C18H18. Molecular Weight: 234.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
MD COVID-19 - Vaccination Percent Age Group Population

Regarding all Vaccination Data
The date of Last Update is 4/21/2023. Additionally on 4/27/2023 several COVID-19 datasets were retired and no longer included in public COVID-19 data dissemination.

See this link for more information
https://imap.maryland.gov/pages/covid-data

<b>Summary</b>
The cumulative number of COVID-19 vaccinations percent age group population: 16-17; 18-49; 50-64; 65 Plus.

<b>Description</b>
 COVID-19 - Vaccination Percent Age Group Population data layer is a collection of COVID-19 vaccinations that have been reported each day into ImmuNet.

COVID-19 is a disease caused by a respiratory virus first identified in Wuhan, Hubei Province, China in December 2019. COVID-19 is a new virus that hasn't caused illness in humans before. Worldwide, COVID-19 has resulted in thousands of infections, causing illness and in some cases death. Cases have spread to countries throughout the world, with more cases reported daily. The Maryland Department of Health reports daily on COVID-19 cases by county.

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the Data) is provided as is without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata. This map is for planning purposes only. MEMA does not guarantee the accuracy of any forecast or predictive elements.
Losartan potassium and hydrochlorothiazide

Losartan Potassium and Hydrochlorothiazide is a prescription medication combining an angiotensin II receptor blocker and a thiazide diuretic to treat high blood pressure. Available as oral tablets in strengths like 50mg/12.5mg, 100mg/12.5mg, and 100mg/25mg, it's a generic version manufactured by Jubilant Cadista Pharmaceuticals Inc. This information was generated using AI and is provided for informational and research purposes only.
EO 14218 - Letter to State, Local, Tribal Partners

Dear State, Tribal, Territorial, and Local Government Partners, On February 19, 2025, President Trump issued an Executive Order titled “Ending Taxpayer Subsidization of Open Borders
  
  

.” As the Acting Assistant Secretary for Children and Families, I am committed to faithfully implementing the President's Executive Order. The Administration for Children and Families (ACF) at the U.S. Department of Health and Human Services provides federal leadership, partnership, and resources for the compassionate and effective delivery of human services to vulnerable populations to help families achieve prosperity and independence. Program eligibility rules are determined by Congress. In 1996, Congress passed the Personal Responsibility and Work Opportunity Reconciliation Act (PRWORA, P.L. 104-193) that generally prohibits illegal aliens from receiving Federal benefits, including Temporary Assistance for Needy Families (TANF), Child-Care, Low-Income Home Energy Assistance Program, Foster Care, Social Services Block Grant (SSBG). Title IV of the PRWORA states that “[i]t is a compelling government interest to remove the incentive for illegal immigration provided by the availability of public benefits.” Nearly three decades after enactment, the promise of PRWORA has been eroded. That ends now. Illegal aliens have already violated United States law and we will not be spending taxpayer dollars to take care of their needs. President Trump's Executive Order reaffirms this important national policy and puts the needs of Americans first. To implement the President’s Executive Order, ACF will use all available legal authority to end any incentives in human services programs that encourage illegal immigration. To that end, ACF is reviewing the public benefit programs we administer to ensure alignment with the President's Executive Order. Following that review, ACF will implement necessary changes so all its programs are consistent with Federal law, including PRWORA. ACF will also work to ensure that all information about program eligibility is accurate and does not serve as an incentive to encourage illegal migration. Furthermore, ACF will take all necessary measures to improve eligibility verification, deter fraud, and enforce the law by revoking grants to organizations that distribute benefits to illegal aliens in contravention of federal or state law. I look forward to working with State, Tribal, territorial, and local government partners to achieve the purpose of the President's Executive Order. I am confident its implementation will improve program integrity, exercise sound stewardship of taxpayer dollars, and better support our Nation’s children and families. Thank you for your continued work to help address the human service needs of vulnerable Americans. I welcome any ideas you might have in improving the administration of ACF programs and achieving alignment with the President's Executive Order.

Sincerely, Andrew Gradison Acting Assistant Secretary

Metadata-only record linking to the original dataset. Open original dataset below.
Hospital Cost Report Edited Data Print Image: 2010

The Institutional Cost Report (ICR) is a uniform report completed by New York hospitals to report income, expenses, assets, liabilities, and statistics to the Department of Health (DOH). Under DOH regulations, (Part 86-1.2), Article 28 hospitals are required to file financial and statistical data with DOH annually. The data filed is part of the ICR and is received electronically through a secured network. This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends. This dataset includes the print image of the edited data.  The ICR is a comprehensive compilation of exhibits that have been modified over time that users should consider when using the ICR dataset. It is possible that data is updated subsequent to posting on this website; therefore the data could become obsolete. To get the details related to the exhibits and data elements, please refer to the blank ICR form, the ICR Table of Contents, the ICR Instructions and the Glossary of Terms, Acronyms, and Abbreviations which are in the Supporting Information section of this site. The data posted as edited contains desk edit adjustments by DOH personnel. In 2009, this information was not audited; however effective with the 2010 ICR, all ICRs will be audited by a Certified Public Accounting Firm annually.
Tribal and Native American Organization Funding

ACF’s programs help address COVID-19 recovery and support the needs of children, youth, and families. This page provides information on new funding announcements, ACF programs that are available to Tribes and Native communities, ACF tribal and Native organization funding recipients, and other useful funding-related information. ACF’s programs awarded $1.76 billion in supplemental COVID-19 funding to tribes and Native communities. These funds are in addition to the more than $1 billion the agency awards to tribes and Native communities each year.

Open ACF Notice of Funding Opportunity (NOFO) Announcements

You can explore a list of ACF Program Office’s NOFOs here that are currently open and accepting applications.

Forecast synopses and all full competitive ACF NOFOs are posted at Grants.gov
  
  

  — the same place you will go to submit your application

Helpful Tip: Keeping Up-to-Date

Register on Grants.gov
  
  

  to create an account and receive email notifications when there are changes to your chosen funding opportunities.

COVID-19 Supplemental Funds FY2020 (XLSX)

COVID-19 Supplemental Funds FY2021 (XLSX)

GY 2022 CCDF Tribal Allocations (Based on Appropriations)

GY 2021 CCDF Final Tribal Allocations

FY 2022 ACF Tribal and Native Organizations Funding Report (XLSX)

Explore the Tribes and Native organizations that received ACF Program Office funding in FY 2022 in this report.

FY 2021 ACF Tribal and Native Organizations Funding Report (XLSX)

Explore the Tribes and Native organizations that received ACF Program Office funding in FY 2021 in this report.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 527791: Prop-2-ynyl 3-chlorobenzoate

Chemical compound data from PubChem database. IUPAC Name: prop-2-ynyl 3-chlorobenzoate. Molecular Formula: C10H7ClO2. Molecular Weight: 194.61. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Nh3n13

Ammonia N 13 is a radioactive diagnostic agent used in medical imaging, particularly for positron emission tomography (PET) scans to assess heart function. It is administered intravenously as an injection, with strengths ranging from 30-300 mCi in 8 mL. Manufactured by UCSF Radiopharmaceutical Facility, it's available as a prescription drug under ANDA204496. This information was generated using AI and is provided for informational and research purposes only.
Compound 526976: (10,13-Dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl) decanoate

Chemical compound data from PubChem database. IUPAC Name: (10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl) decanoate. Molecular Formula: C29H48O3. Molecular Weight: 444.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Cell-cell interactions in synovitis: Interactions between T cells and B cells in rheumatoid arthritis

In rheumatoid arthritis, T cells and B cells participate in the immune responses evolving in the synovial lesions. Interaction between T cells and B cells is probably antigen specific because complex microstructures typical of secondary lymphoid organs are generated. Differences between patients in forming follicles with germinal centers, T-cell–B-cell aggregates without germinal center reactions, or loosely organized T-cell–B-cell infiltrates might reflect the presence of different antigens or a heterogeneity in host response patterns to immune injury. Tertiary lymphoid microstructures in the rheumatoid lesions can enhance the sensitivity of antigen recognition, optimize the collaboration of immunoregulatory and effector cells, and support the interaction between the tissue site and the aberrant immune response. The molecular basis of lymphoid organogenesis studied in gene-targeted mice will provide clues to why the synovium is a preferred site for tertiary lymphoid tissue. B cells have a critical role in lymphoid organogenesis. Their contribution to synovial inflammation extends beyond antibody secretion and includes the activation and regulation of effector T cells.